
Opinion|Videos|April 25, 2024
Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
2
Taylor Goodstein, MD, highlights contemporary experience with gene therapies for NMIBC
3
Real-World Evidence in mCSPC Management
4
Jim Hu, MD, discusses new posterior approach to nerve-sparing prostatectomy
5


















